The University of Southampton
University of Southampton Institutional Repository

What do cancer-specific CD8+ T cells see?: the contribution of immunopeptidomics

What do cancer-specific CD8+ T cells see?: the contribution of immunopeptidomics
What do cancer-specific CD8+ T cells see?: the contribution of immunopeptidomics

Immunopeptidomics is the survey of all peptides displayed on a cell or tissue when bound to human leukocyte antigen (HLA) molecules using tandem mass spectrometry. When attempting to determine the targets of tumour-specific CD8+ T cells, a survey of the potential ligands in tumour tissues is invaluable, and, in comparison with in-silico predictions, provides greater certainty of the existence of individual epitopes, as immunopeptidomics-confirmed CD8+ T-cell epitopes are known to be immunogenic, and direct observation should avoid the risk of autoreactivity which could arise following immunisation with structural homologues. The canonical sources of CD8+ T-cell tumour specific epitopes, such as tumour associated antigens, may be well conserved between patients and tumour types, but are often only weakly immunogenic. Direct observation of tumour-specific neoantigens by immunopeptidomics is rare, although valuable. Thus, there has been increasing interest in the non-canonical origins of tumour-reactive CD8+ T-cell epitopes, such as those arising from proteasomal splicing events, translational/turnover defects and alternative open reading frame reads. Such epitopes can be identified in silico, although validation is more challenging. Non-self CD8+ T-cell epitopes such as viral epitopes may be useful in certain cancer types with known viral origins, however these have been relatively unexplored with immunopeptidomics to date, possibly due to the paucity of source viral proteins in tumour tissues. This review examines the latest evidence for canonical, non-canonical and non-human CD8+ T-cell epitopes identified by immunopeptidomics, and concludes that the relative contribution for each of these sources to anti-tumour CD8+ T-cell reactivity is currently uncertain.

1744-1358
957-965
Nicholas, Ben
01cab7d7-32c0-413f-804b-d4133070268b
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Nicholas, Ben
01cab7d7-32c0-413f-804b-d4133070268b
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5

Nicholas, Ben and Skipp, Paul (2023) What do cancer-specific CD8+ T cells see?: the contribution of immunopeptidomics. Essays in Biochemistry, 67 (6), 957-965. (doi:10.1042/EBC20220246).

Record type: Review

Abstract

Immunopeptidomics is the survey of all peptides displayed on a cell or tissue when bound to human leukocyte antigen (HLA) molecules using tandem mass spectrometry. When attempting to determine the targets of tumour-specific CD8+ T cells, a survey of the potential ligands in tumour tissues is invaluable, and, in comparison with in-silico predictions, provides greater certainty of the existence of individual epitopes, as immunopeptidomics-confirmed CD8+ T-cell epitopes are known to be immunogenic, and direct observation should avoid the risk of autoreactivity which could arise following immunisation with structural homologues. The canonical sources of CD8+ T-cell tumour specific epitopes, such as tumour associated antigens, may be well conserved between patients and tumour types, but are often only weakly immunogenic. Direct observation of tumour-specific neoantigens by immunopeptidomics is rare, although valuable. Thus, there has been increasing interest in the non-canonical origins of tumour-reactive CD8+ T-cell epitopes, such as those arising from proteasomal splicing events, translational/turnover defects and alternative open reading frame reads. Such epitopes can be identified in silico, although validation is more challenging. Non-self CD8+ T-cell epitopes such as viral epitopes may be useful in certain cancer types with known viral origins, however these have been relatively unexplored with immunopeptidomics to date, possibly due to the paucity of source viral proteins in tumour tissues. This review examines the latest evidence for canonical, non-canonical and non-human CD8+ T-cell epitopes identified by immunopeptidomics, and concludes that the relative contribution for each of these sources to anti-tumour CD8+ T-cell reactivity is currently uncertain.

Text
EIB_BLN_2023-06-19-revise_wrefs[63] - Accepted Manuscript
Download (250kB)

More information

Accepted/In Press date: 13 July 2023
e-pub ahead of print date: 28 July 2023
Published date: 28 September 2023
Additional Information: Publisher Copyright: © 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Identifiers

Local EPrints ID: 482857
URI: http://eprints.soton.ac.uk/id/eprint/482857
ISSN: 1744-1358
PURE UUID: b1f8d164-ac72-4924-9b54-a1b3646ea608
ORCID for Paul Skipp: ORCID iD orcid.org/0000-0002-2995-2959

Catalogue record

Date deposited: 13 Oct 2023 16:51
Last modified: 18 Mar 2024 02:38

Export record

Altmetrics

Contributors

Author: Ben Nicholas
Author: Paul Skipp ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×